Rep. Lisa C. McClain Sells Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Key Points

• Representative Lisa C. McClain sold shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) worth between $1,001 and $15,000 on June 17, as disclosed on August 13.
• Neurocrine Biosciences reported earnings of $1.06 per share for the last quarter, exceeding estimates, and achieved revenues of $687.5 million, marking a 16.5% increase year-over-year.
• Analyst ratings for Neurocrine Biosciences are generally positive, with a consensus price target of $159.50, indicating a moderate buy sentiment from investors.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Neurocrine Biosciences, Inc. NASDAQ: NBIX. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Neurocrine Biosciences stock on June 17th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Neurocrine Biosciences Trading Up 0.3%

Neurocrine Biosciences stock opened at $133.23 on Thursday. The business's fifty day simple moving average is $129.70 and its two-hundred day simple moving average is $119.44. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $154.87. The company has a market capitalization of $13.21 billion, a price-to-earnings ratio of 39.42, a price-to-earnings-growth ratio of 0.96 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. The business had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.63 earnings per share. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Activity at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 457 shares of the business's stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares in the company, valued at $638,550. The trade was a 8.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the sale, the director directly owned 514,596 shares of the company's stock, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 196,573 shares of company stock worth $25,112,766 in the last quarter. 4.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NBIX shares. Wedbush upped their price target on Neurocrine Biosciences from $137.00 to $141.00 and gave the company an "outperform" rating in a report on Thursday, July 31st. UBS Group upped their price target on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a report on Wednesday, July 9th. Evercore ISI lowered their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada lowered their price target on Neurocrine Biosciences from $146.00 to $144.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Finally, Morgan Stanley upped their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company an "overweight" rating in a report on Thursday, July 31st. Eighteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $159.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NBIX. Diametric Capital LP boosted its holdings in Neurocrine Biosciences by 2.6% during the 2nd quarter. Diametric Capital LP now owns 3,244 shares of the company's stock valued at $408,000 after acquiring an additional 81 shares during the period. OneDigital Investment Advisors LLC boosted its holdings in Neurocrine Biosciences by 2.1% during the 4th quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock valued at $575,000 after acquiring an additional 87 shares during the period. IFP Advisors Inc boosted its holdings in Neurocrine Biosciences by 4.2% during the 2nd quarter. IFP Advisors Inc now owns 2,172 shares of the company's stock valued at $273,000 after acquiring an additional 88 shares during the period. Linden Thomas Advisory Services LLC boosted its holdings in Neurocrine Biosciences by 1.5% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company's stock valued at $842,000 after acquiring an additional 96 shares during the period. Finally, Utah Retirement Systems boosted its holdings in Neurocrine Biosciences by 0.6% during the 4th quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock valued at $2,264,000 after acquiring an additional 100 shares during the period. Institutional investors own 92.59% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.